Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening.

Studies of the type 3 secretion system (T3SS) in Pseudomonas aeruginosa isolates from chronically infected older children and adults with cystic fibrosis (CF) show a predominantly exoS+/exoU- (exoS+) genotype and loss of T3SS effector secretion over time. Relatively little is known about the role of the T3SS in the pathogenesis of early P. aeruginosa infection in the CF airway. In this longitudinal study, 168 P. aeruginosa isolates from 58 children diagnosed with CF following newborn screening and 47 isolates from homes of families with or without children with CF were genotyped by pulsed-field gel electrophoresis (PFGE) and T3SS genotype and phenotype determined using multiplex PCR and western blotting. Associations were sought between T3SS data and clinical variables and comparisons made between T3SS data of clinical and environmental PFGE genotypes. Seventy-seven of the 92 clinical strains were exoS+ (71% secretors (ExoS+)) and 15 were exoU+ (93% secretors (ExoU+)). Initial exoS+ strains were five times more likely to secrete ExoS than subsequent exoS+ strains at first isolation. The proportion of ExoS+ strains declined with increasing age at acquisition. No associations were found between T3SS characteristics and gender, site of isolation, exacerbation, a persistent strain or pulmonary outcomes. Fourteen of the 23 environmental strains were exoS+ (79% ExoS+) and nine were exoU+ (33% ExoU+). The exoU+ environmental strains were significantly less likely to secrete ExoU than clinical strains. This study provides new insight into the T3SS characteristics of P. aeruginosa isolated from the CF airway early in life.

[1]  J. Carlin,et al.  Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. , 2011, JAMA.

[2]  P. Mogayzel,et al.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. , 2010, Paediatric respiratory reviews.

[3]  J. Lipuma The Changing Microbial Epidemiology in Cystic Fibrosis , 2010, Clinical Microbiology Reviews.

[4]  D. Hassett,et al.  Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies , 2010, Expert opinion on therapeutic targets.

[5]  A. Hauser The type III secretion system of Pseudomonas aeruginosa: infection by injection , 2009, Nature Reviews Microbiology.

[6]  M. Elkins,et al.  Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients , 2009, Journal of Clinical Microbiology.

[7]  J. Engel,et al.  Role of Pseudomonas aeruginosa type III effectors in disease. , 2009, Current opinion in microbiology.

[8]  S. Bell,et al.  Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. , 2009, Diagnostic microbiology and infectious disease.

[9]  S. McColley,et al.  Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection. , 2008, Translational research : the journal of laboratory and clinical medicine.

[10]  N. Høiby,et al.  Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  D. Wareham,et al.  A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. , 2007, International journal of medical microbiology : IJMM.

[12]  R. Koski,et al.  Annals of Clinical Microbiology and Antimicrobials Open Access an Indirect Enzyme-linked Immunosorbent Assay for Rapid and Quantitative Assessment of Type Iii Virulence Phenotypes of Pseudomonas Aeruginosa Isolates , 2005 .

[13]  J. Carlin,et al.  Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. , 2005, American journal of respiratory and critical care medicine.

[14]  Vincent T. Lee,et al.  Activities of Pseudomonas aeruginosa Effectors Secreted by the Type III Secretion System In Vitro and during Infection , 2005, Infection and Immunity.

[15]  A. Hauser,et al.  Relative Contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to Virulence in the Lung , 2004, Infection and Immunity.

[16]  S. McColley,et al.  Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis , 2004, Journal of Clinical Microbiology.

[17]  S. Bell,et al.  Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units , 2004, European Respiratory Journal.

[18]  P. Molina,et al.  High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. , 2004, The Journal of pediatrics.

[19]  J. Rello,et al.  Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. , 2003, The Journal of infectious diseases.

[20]  J. Wiener-Kronish,et al.  Single-Nucleotide-Polymorphism Mapping of the Pseudomonas aeruginosa Type III Secretion Toxins for Development of a Diagnostic Multiplex PCR System , 2003, Journal of Clinical Microbiology.

[21]  M. Elkins,et al.  Genetic Analysis of Pseudomonas aeruginosa Isolates from the Sputa of Australian Adult Cystic Fibrosis Patients , 2002, Journal of Clinical Microbiology.

[22]  A. Hauser,et al.  Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. , 2001, Microbiology.

[23]  R. Savel,et al.  Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. , 2001, The Journal of infectious diseases.

[24]  J. Emerson,et al.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. , 2001, The Journal of infectious diseases.

[25]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[26]  F. Ausubel,et al.  Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[28]  D. Woods,et al.  Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. , 1993, Pediatric pulmonology.